Top Page
Fusen Pharmaceutical Co., Ltd.
(1652)
Fusen Pharmaceutical Co., Ltd. (1652) vs. iShares MSCI Hong Kong ETF (EWH)
Fusen Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Fusen Pharmaceutical Co., Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 326.03M | 565.61M | 491.76M | 385.66M | 486.85M |
| Gross Profit | 162.64M | 299.51M | 225.02M | 211.13M | 266.07M |
| EBITDA | -39.07M | 18.93M | 49.90M | 86.84M | 110.30M |
| Net Income | -188.78M | -36.28M | -34.65M | 16.64M | 70.13M |
Balance Sheet | |||||
| Total Assets | 1.24B | 1.34B | 1.35B | 1.24B | 1.24B |
| Cash, Cash Equivalents and Short-Term Investments | 21.06M | 34.85M | 128.11M | 81.70M | 312.53M |
| Total Debt | 383.69M | 344.12M | 228.38M | 240.69M | 198.50M |
| Total Liabilities | 869.80M | 781.52M | 737.38M | 582.39M | 583.10M |
| Stockholders Equity | 369.67M | 563.52M | 614.17M | 658.17M | 659.44M |
Cash Flow | |||||
| Free Cash Flow | 57.43M | -161.84M | 86.63M | -62.37M | 94.56M |
| Operating Cash Flow | 133.73M | -73.33M | 110.49M | 47.77M | 153.21M |
| Investing Cash Flow | -163.42M | -108.32M | -13.13M | -282.98M | -68.20M |
| Financing Cash Flow | 15.99M | 88.50M | -51.77M | 20.53M | -116.33M |
Fusen Pharmaceutical Co., Ltd. Technical Analysis
Fusen Pharmaceutical Co., Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$525.14M | 23.57 | 1.87% | 8.06% | -1.99% | -81.52% | |
| ― | HK$275.26M | ― | -8.71% | ― | 2.54% | 33.33% | |
| ― | HK$691.11M | ― | -40.38% | ― | -43.46% | -96.48% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | HK$169.82M | ― | -33.22% | ― | -17.32% | 55.74% | |
| ― | HK$566.37M | -3.33 | ― | ― | ― | ― |
Fusen Pharmaceutical Co., Ltd. Corporate Events
Fusen Pharmaceutical Co., Ltd. announced the approval of its ‘Enzalutamide Soft Capsule’ for marketing in China, targeting non-metastatic and metastatic castration-resistant prostate cancer. This product, developed by its subsidiary Jiaheng Pharmaceutical Technology, aligns with international standards and offers a favorable risk-benefit ratio for patients, enhancing the company’s therapeutic offerings and potentially strengthening its market position in prostate cancer treatment.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Co., Ltd. announced that its Metformin Empagliflozin Tablets were selected in the eleventh batch of China’s National Centralised Medicines Procurement. This selection is a significant development for the company, potentially enhancing its market position and offering growth opportunities in the Chinese pharmaceutical market.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Co., Ltd. announced a supplemental disclosure regarding the disposal of its entire equity interests in Henan Fusen Intelligent Energy Conservation Technology Co., Ltd. The consideration for this transaction was determined through negotiations based on the appraised net asset value of approximately RMB73.4 million. The valuation, conducted by an independent valuer, utilized the asset approach due to the target company’s short operational history, making other valuation methods less reliable.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Company Limited has announced the composition of its board of directors and their respective roles, highlighting the leadership structure within the company. The announcement details the membership of three board committees, which are crucial for the company’s governance and operational oversight, potentially impacting its strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Co., Ltd. has announced significant changes in its board composition effective from September 30, 2025. Mr. Sze Wing Chun has resigned as an independent non-executive director and chairman of the Audit Committee, while Mr. Yu Ho Ming has been appointed as an independent non-executive director and a member of the Audit Committee. Additionally, Mr. Lee Kwok Tung Louis has been appointed as the chairman of the Audit Committee. These changes are expected to bring new expertise and perspectives to the company’s governance, potentially impacting its strategic direction and stakeholder relations.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Co., Ltd. has announced a discloseable transaction involving the sale of its entire equity interests in Henan Fusen Intelligent Energy Conservation Technology Company Limited. The transaction is valued at RMB73.0 million and involves a conditional agreement with a purchaser owned by state and local government authorities in China. This strategic move is part of Fusen Pharmaceutical’s efforts to streamline its operations and focus on its core business areas. The disposal is subject to certain conditions and regulatory requirements, and stakeholders are advised to exercise caution.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Co., Ltd. has announced the approval of its ‘Metformin Empagliflozin Tablets (I)’ by the National Medical Products Administration of China for the treatment of type 2 diabetes. This new product, which combines Metformin and Empagliflozin, is expected to enhance the company’s product pipeline in diabetes care, offering a synergistic hypoglycemic effect and better patient tolerance. The approval aligns with China’s national health goals, potentially increasing demand for diabetes medications and strengthening Fusen’s market position in the industry.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Co., Ltd. reported a significant decline in its financial performance for the first half of 2025, with revenue dropping by 43.3% and gross profit decreasing by 59.4% compared to the same period in 2024. Despite the reduced losses attributable to equity shareholders, the company continues to face challenges in its operations, impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Co., Ltd. has announced a board meeting scheduled for August 29, 2025, to review and approve the company’s unaudited interim results for the first half of the year and to consider declaring an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential shareholder returns.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.